Pulmonary Edema Therapeutics Market Size to Grow by USD 339.45 million, High Prevalence of Risk Factors to Boost Market Growth - Technavio
NEW YORK, Aug. 16, 2022 /PRNewswire/ -- The "Pulmonary Edema Therapeutics Market by Type (Cardiogenic pulmonary edema and Non-cardiogenic pulmonary edema) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The potential growth difference for the pulmonary edema therapeutics market size between 2021 and 2026 is USD 339.45 mn. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report
Key Market Dynamics:
Market Driver: The high prevalence of risk factors is driving the growth of the market. Pulmonary edema is a leading cause of death among adults living in developing countries. Heart failure is one of the most common causes of cardiogenic pulmonary edema, which is a condition wherein the left ventricle is unable to pump the adequate volume of blood required to meet the needs of the body. Pulmonary edema is one of the leading causes of death in adults living in developing countries. Lung diseases can be caused by individuals that have been exposed to chemicals during industrial accidents. Trauma as a result of accidents can also cause pulmonary edema. Thus, the high prevalence of risk factors is driving the growth of the global pulmonary edema market.
Market Challenge: Adverse effects of available therapeutics are challenging the growth of the market. These effects include headache, fever, chills, nausea, and vomiting. For instance, DEMADEX is used for treating hypertension and edema caused by heart, liver, or kidney diseases. However, the common side effects of DEMADEX include sore throat, constipation, frequent urination, weakness, and others. Such adverse effects can hinder patient adherence to the treatment regimen, which will hamper the pulmonary edema therapeutics market growth during the forecast period.
The cardiogenic pulmonary edema segment will contribute the highest market share growth during the forecast period. The growth of this segment is mainly attributed to factors such as a high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension. Cardiogenic pulmonary edema is a result of increased pressure in the heart.
North America will be the leading region with 35% of the market's growth during the forecast period. The US and Canada are the key countries for the pulmonary edema therapeutics market in North America. The growth of this region is attributed to factors such as the high prevalence of risk factors and increasing approval of drugs to treat pulmonary edema. Market growth in this region will be faster than the growth of the market in other regions.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Buy Now to access exclusive information about the segments
Some Companies Mentioned
AbbVie Inc.
ADVANZ PHARMA Corp.
Apotex Inc.
Bausch Health Companies Inc.
CHIESI Farmaceutici SpA
CMP Pharma Inc.
Johnson and Johnson
Lupin Ltd.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Validus Pharmaceuticals LLC
Want your report customized? Speak to an analyst and personalize your report according to your needs.
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 35%
Key consumer countries
US, Canada, Germany, UK, and China
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
AbbVie Inc., ADVANZ PHARMA Corp., Apotex Inc., Bausch Health Companies Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Validus Pharmaceuticals LLC
Market Dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Exhibit 131: Validation techniques employed for market sizing
Exhibit 132: Information sources
11.5 List of abbreviations
Exhibit 133: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ("Nextdoor" or "the Company") for violations...
Escalade, Inc. , a leading manufacturer and distributor of sporting goods and indoor/outdoor recreational equipment, today announced that it will issue first quarter 2024 results before the market opens on Thursday, April 25, 2024.
A conference call...
Great Neck Realty Co. is marketing the intellectual property (the "Assets") of BOA Nutrition, Inc., ("Company" or "BOA"), an innovative sports nutrition and wellness company that specialized in producing oral aerosol energy supplements tailored to...
West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") reported today the first quarter results of 2024 ("Q1-24"). All dollar amounts in this news release are expressed in U.S. dollars unless noted otherwise.
First Quarter Highlights?
Sales...
Modine , a diversified leader in thermal management technologies and solutions, officially marked the opening of a second facility in Sremska, Serbia, to manufacture coils for commercial and residential heat pump applications. Serbian Prime...